Table 6.2Selected Initiatives of the TDR

Disease Product Partner Status
Uncomplicated malariaLapdapGlaxoSmithKlineDossier submitted (2002)
Lapdap, artesunateGlaxoSmithKlinePhase 1
Pyronaridine, artesunateShin PoongPreclinical trials
Severe malariaIntramuscular artemetherArtecefRegistered (2000)
Rectal artesunateUnder discussionFDA approval letter received
Visceral leishmaniasisMiltefosineZentarisRegistered (2002)
ParomomycinInstitute for One World HealthPhase 3 studies
Sleeping sicknessIntravenous eflornithineAventisRegistered (2001)
River blindnessIvermectinMerckRegistered (1989)

Source: Ridley 2003.

From: Chapter 6, Product Development Priorities

Cover of Disease Control Priorities in Developing Countries
Disease Control Priorities in Developing Countries. 2nd edition.
Jamison DT, Breman JG, Measham AR, et al., editors.
Copyright © 2006, The International Bank for Reconstruction and Development/The World Bank Group.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.